# Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients

> **NCT03925090** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 150 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Cisplatin+Toripalimab
- **DRUG:** Cisplatin+placebo

## Key facts

- **NCT ID:** NCT03925090
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-08
- **Primary completion:** 2021-12-06
- **Final completion:** 2023-10
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03925090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03925090, "Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT03925090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*